2020 Revenues ($USD) : $42,518,000,000
2020 R&D spend : $11,143,000,000
2020 Number of Employees : 30,250
Fiscal Year End : 12/31/2020
Key People : Dr. Giovanni Caforio, chair and CEO; Chris Boerner, EVP and chief commercialization officer; Adam Dubow, SVP and chief compliance and ethics officer; Dr. Joseph E. Eid, SVP and head of global medical affairs; David Elkins, EVP and CFO; Dr. Samit Hirawat, EVP, chief medical officer, global drug development; Sandra Leung, EVP, general counsel; Elizabeth A. Mily, EVP, strategy & business development; Ann M. Powell, EVP, chief human resources officer; Lou Schmukler, EVP and president, global product development & supply; Catalina Vargas, chief of staff to the CEO; Rupert Vessey, EVP and president, research and early development; Paul von Autenried, EVP, CIO

Tracing its origins back to the Squibb corporation founding in 1858, Bristol Myers Squibb makes several blockbuster drugs. Its bestselling drugs include the cancer immunotherapy Opdivo (2020 sales of $7 billion), the rheumatoid arthritis treatment Orencia ($3.2 billion) and the chemotherapy Sprycel ($2.1 billion). Its bestselling drug chemotherapy drug Revlimid, however, was acquired through its 2019 acquisition of Celgene for $74 billion. Revlimid sales hit $12 billion last year. The company's appetite for substantial acquisitions continued into 2020. In October, it announced its intent to purchase the biopharma MyoKardia for roughly $13.1 billion in cash. —BB